KRM Ayurveda AGM votes and auditors
NSE: KRMAYURVEDPharmaceuticals & Biotechnology
Share price at the NSE close on 30 Oct 2026. Previous close ₹236.00.
30 Oct: open ₹236.00, high ₹238.00, low ₹223.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹479 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.18
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Jan 2026
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 54,00055.6% delivered
KRM Ayurveda board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Shiv & AssociatesPeer-review certificate valid to Jul 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
KRM Ayurveda AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.KRM Ayurveda share news and announcements
Annual general meeting, 30 Sep 2026
1,013 shareholders on the register on 23 Sep 2026; present: 4 promoters and 12 others; votes counted by AMIT KUMAR MANGLA / AMIT K MANGLA & CO..The company's voting result
To receive, consider and adopt the Audited Financial Statements (Standalone) for the financial year ended on the 31st March, 2026 together with the reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.20% · promoters 99.97% · institutions 0.00% · other public 11.22%
- To re-appoint Mr. Puneet Dhawan (DIN:08553667) as a Director who retires by rotation and being eligible, offers himself for re-appointment, as a Director of the Company.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.20% · promoters 99.97% · institutions 0.00% · other public 11.22%
- To fix renumerfation of Mr. Puneet Dhawan, Managing Director of the Company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.20% · promoters 99.97% · institutions 0.00% · other public 11.22%
- To approve related party transactions.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 2.81% · promoters 0.00% · institutions 0.00% · other public 10.82%
- To approve appointment of Secretarial AuditorOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.15% · promoters 99.97% · institutions 0.00% · other public 11.06%
- To approve variation/adjustment in utilization of IPO proceeds and authorization for utilization of balance IPO proceeds towards General Corporate Purposes.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 72.20% · promoters 99.97% · institutions 0.00% · other public 11.22%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Mar 2026. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A statement's amounts are left out where the raise it states is more than ten times everything the company owns, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Public IssuesJan 2026, checked by CARE RATINGS LIMITED | – | – | – | No |